Advertisement

Topics

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

13:00 EDT 10 Aug 2018 | Xconomy

[Updated at 3:25 pm ET, see below] Alnylam Pharmaceuticals made history this afternoon. The FDA has just approved Alnylam’s patisiran (Onpattro), making it the first medicine specifically cleared to treat a rare and deadly disease called hereditary transthyretin amyloidosis (hATTR). The decision is a scientific milestone too: it marks the first-ever approval for a medicine […]

Original Article: Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

NEXT ARTICLE

More From BioPortfolio on "Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug"

Advertisement
Quick Search
Advertisement
Advertisement